Table A.13 Median Age At Start Of Esrd Therapy By Year, By Race, Sex, and Primary Disease Causing ESRD ------------------------------------------------------------------------------------------------ | | 1987 | 1988 | 1989 | 1990 | 1991 | 1992 | 1993 | 1994 | 1995 | 1996 | |----------------------------------+------+------+------+------+------+------+------+------+------+------| |Age 0-19 | 15.0| 15.0| 15.0| 15.0| 14.0| 15.0| 14.0| 14.0| 14.0| 14.0| | 20-44 | 35.0| 35.0| 35.0| 35.0| 36.0| 36.0| 36.0| 36.0| 36.0| 37.0| | 45-64 | 57.0| 57.0| 57.0| 57.0| 57.0| 57.0| 56.0| 56.0| 56.0| 56.0| | 65-74 | 69.0| 69.0| 69.0| 69.0| 69.0| 69.0| 69.0| 69.0| 69.0| 70.0| | 75 plus | 78.0| 78.0| 79.0| 79.0| 79.0| 79.0| 79.0| 79.0| 79.0| 79.0| |Disease 1 Diabetes | 59.0| 59.0| 60.0| 61.0| 61.0| 62.0| 62.0| 62.0| 62.0| 62.0| | 2 Hypertension | 66.0| 67.0| 67.0| 68.0| 68.0| 68.0| 69.0| 68.0| 69.0| 69.0| | 3 Glomeruloneph. | 52.0| 52.0| 53.0| 53.0| 54.0| 54.0| 54.0| 54.0| 53.0| 53.0| | 4 Cystic Kidney | 55.0| 53.0| 53.5| 54.0| 54.0| 54.0| 53.0| 54.0| 53.0| 53.0| | 5 Other Urologic | 68.0| 68.0| 69.0| 67.0| 62.0| 64.0| 62.0| 63.0| 65.0| 65.0| | 6 Other Cause | 56.0| 56.0| 57.0| 56.0| 58.0| 58.0| 57.0| 56.0| 56.0| 57.0| | 7 Unknown Cause | 64.0| 65.0| 65.0| 65.0| 65.0| 65.0| 65.0| 64.0| 66.0| 66.0| | 8 Missing Cause | 58.0| 58.0| 64.0| 63.0| 63.0| 65.0| 69.0| 65.0| 66.0| 49.0| |Race 1 Native Amer. | 57.0| 57.0| 59.0| 58.0| 58.0| 60.0| 60.0| 58.0| 58.0| 57.0| | 2 Asian | 58.0| 58.5| 60.0| 60.0| 61.0| 61.0| 62.0| 62.0| 62.0| 63.0| | 3 Black | 58.0| 57.0| 58.0| 59.0| 59.0| 59.0| 59.0| 58.0| 57.0| 57.0| | 4 White | 62.0| 63.0| 64.0| 64.0| 65.0| 65.0| 66.0| 65.0| 65.0| 66.0| | 5 Unknown | 64.0| 64.0| 72.0| 72.0| 71.0| 71.0| 72.0| 68.0| 70.0| 56.5| | 9 Other | 55.5| 56.0| 56.0| 45.5| 45.5| 57.0| 61.0| 56.0| 56.0| 56.0| |Sex Female | 62.0| 62.0| 63.0| 63.0| 64.0| 64.0| 65.0| 64.0| 64.0| 64.0| | Male | 60.0| 60.0| 61.0| 61.0| 62.0| 62.0| 63.0| 62.0| 62.0| 62.0| |Total Total | 61.0| 61.0| 62.0| 62.0| 63.0| 63.0| 64.0| 63.0| 63.0| 63.0| ---------------------------------------------------------------------------------------------------------- Table A.14 Mean Age At Start Of Esrd Therapy By Year, By Race, Sex, and Primary Disease Causing ESRD ------------------------------------------------------------------------------------------------ | | 1987 | 1988 | 1989 | 1990 | 1991 | 1992 | 1993 | 1994 | 1995 | 1996 | |----------------------------------+------+------+------+------+------+------+------+------+------+------| |Age 0-19 | 12.8| 12.9| 13.1| 12.7| 12.3| 12.9| 12.5| 12.7| 12.2| 12.3| | 20-44 | 34.2| 34.2| 34.3| 34.6| 34.9| 34.9| 34.9| 34.9| 35.2| 35.4| | 45-64 | 56.1| 56.1| 56.0| 56.0| 56.0| 55.9| 55.8| 55.7| 55.6| 55.5| | 65-74 | 69.2| 69.3| 69.3| 69.3| 69.3| 69.4| 69.4| 69.5| 69.5| 69.6| | 75 plus | 79.2| 79.3| 79.5| 79.6| 79.5| 79.7| 79.8| 79.7| 79.8| 79.9| |Disease 1 Diabetes | 56.1| 56.9| 57.3| 58.3| 58.9| 59.3| 59.7| 60.0| 60.3| 60.8| | 2 Hypertension | 63.5| 63.7| 64.1| 64.5| 64.9| 64.9| 65.2| 65.0| 64.8| 65.0| | 3 Glomeruloneph. | 50.7| 50.7| 51.3| 51.7| 52.4| 52.3| 52.3| 52.8| 52.1| 52.8| | 4 Cystic Kidney | 54.1| 53.6| 53.5| 54.0| 53.6| 54.4| 54.2| 54.8| 53.7| 54.3| | 5 Other Urologic | 61.2| 61.7| 62.8| 60.8| 55.2| 56.5| 55.8| 56.5| 59.2| 59.5| | 6 Other Cause | 51.3| 51.5| 52.3| 51.9| 53.3| 54.2| 53.4| 53.1| 53.2| 54.1| | 7 Unknown Cause | 59.6| 60.0| 60.2| 59.6| 59.4| 59.6| 59.2| 58.8| 61.1| 61.0| | 8 Missing Cause | 54.9| 54.9| 60.9| 59.9| 58.7| 61.6| 66.3| 59.8| 61.4| 49.6| |Race 1 Native Amer. | 54.6| 54.7| 56.9| 56.2| 56.2| 58.4| 58.1| 56.2| 56.3| 56.2| | 2 Asian | 55.5| 56.1| 55.5| 56.5| 57.4| 57.2| 58.1| 58.7| 59.7| 60.0| | 3 Black | 55.2| 55.0| 55.3| 55.9| 56.2| 56.4| 56.5| 56.1| 55.6| 55.8| | 4 White | 58.0| 58.7| 59.4| 59.9| 60.6| 61.1| 61.6| 61.7| 61.7| 62.2| | 5 Unknown | 56.9| 60.1| 70.8| 71.3| 70.3| 69.4| 70.4| 64.3| 67.7| 51.8| | 9 Other | 52.5| 52.5| 51.1| 43.3| 45.4| 53.6| 54.8| 51.4| 53.2| 53.1| |Sex Female | 58.2| 58.4| 59.3| 59.7| 60.3| 60.6| 61.2| 60.8| 60.7| 60.8| | Male | 56.2| 56.7| 57.4| 57.8| 58.2| 58.8| 59.0| 58.9| 58.7| 59.2| |Total Total | 57.1| 57.5| 58.3| 58.7| 59.2| 59.6| 60.0| 59.8| 59.6| 59.9| ---------------------------------------------------------------------------------------------------------- Includes all patients: residents of the 50 states, the District of Colulmbia, Puerto Rico and the Territories. * Values for cells with fewer than 10 patients are suppressed. Table A.15 Incidence Of Reported ESRD Therapy Median Age At Incidence, Sex, Race, and One Year Transplant and Death Status By Detailed Primary Disease, For All Patients, 1992-1996 % % Tran % Died Total % Median % % % % Native First First Primary Disease Groups Patients Incid Age Males White Black Asian Amer. Year Year All ESRD, (reference) 332,459 100.0 63 53.2 63.9 29.4 3.1 1.5 5.2 21.5 Diabetes 130,473 40.4 62 47.4 64.2 28.5 3.3 2.4 3.6 20.6 . Type 1, juvenile type 46,100 14.3 57 49.3 70.2 24.9 2.4 1.6 7.3 19.2 . Type 2, adult-onset or unspec. type 84,373 26.1 64 46.3 60.9 30.5 3.8 2.9 1.6 21.4 Glomerulonephritis 36,499 11.3 53 60.8 68.0 24.1 5.0 1.2 11.3 12.3 . Focal glomerulosclerosis, focal GN 6,497 2.0 44 62.8 57.7 37.4 2.7 1.0 13.8 8.2 . Membranous nephropathy 1,554 0.5 57 66.5 71.4 24.2 2.3 1.1 10.9 9.8 . Membranoproliferative GN, types 1&2 1,284 0.4 45 60.4 74.2 16.7 5.5 1.7 17.9 7.9 . IgA nephropathy, Bergers disease 1,080 0.3 40 69.6 74.0 8.5 12.4 1.9 19.0 4.5 . IgM nephropathy 121 0.0 42 66.1 71.1 10.7 13.2 0.8 28.1 3.3 . Rapidly progressive GN 1,336 0.4 61 52.0 80.2 12.9 4.0 1.5 9.0 15.5 . Goodpastures Syndrome 780 0.2 64 47.2 89.4 7.1 1.8 1.2 6.0 24.5 . Post infectious GN, SBE 214 0.1 54 61.7 75.2 19.2 2.3 1.9 8.4 14.0 . Glomerulonephritis (GN) 22,749 7.0 57 60.6 68.4 23.0 5.7 1.3 10.0 13.6 . Other proliferative GN 884 0.3 52 56.8 74.0 18.7 5.4 1.1 13.6 13.1 Secondary GN/Vasculitis 8,122 2.5 45 32.9 63.3 30.6 3.4 1.2 7.4 17.3 . Lupus erythematosus, (SLE nephritis) 4,177 1.3 37 19.4 47.9 44.0 4.8 1.1 8.8 11.2 . Polyarteritis 173 0.1 64 49.1 82.1 11.6 4.6 1.2 5.8 23.7 . Wegeners granulomatosis 890 0.3 64 60.0 91.6 5.4 1.1 1.3 4.6 23.6 . Henoch-Schonlein syndrome 153 0.0 25 56.2 81.7 7.2 6.5 3.3 27.5 7.8 . Vasculitis and its derivatives 467 0.1 68 48.4 88.2 8.1 1.3 1.3 2.6 26.8 . Scleroderma 740 0.2 57 23.4 80.1 17.4 1.1 1.1 2.3 33.9 . Hemolytic uremic syndrome 695 0.2 49 36.5 82.4 15.3 1.3 0.7 7.9 19.6 . Nephropathy from heroin /related abuse 661 0.2 58 62.3 58.7 35.4 2.7 2.0 7.3 20.0 . Secondary GN, other 166 0.1 49 55.4 58.4 34.9 1.8 2.4 3.6 21.1 Interstitial Nephritis/Pyelonephritis 14,577 4.5 64 56.7 79.2 15.9 2.8 1.0 8.1 20.4 . Chronic pyelonephritis, reflux neph. 1,805 0.6 52 38.0 84.2 9.9 3.5 1.1 13.5 13.1 . Analgesic abuse 416 0.1 65 35.3 77.4 18.0 2.4 0.7 2.4 17.5 . Nephropathy caused by other agents 1,865 0.6 66 70.6 77.3 18.8 2.1 0.8 6.0 26.0 . Nephrolithiasis, Obstruction, Gouty 4,078 1.3 67 72.7 78.6 16.3 3.0 0.8 7.0 23.2 . Nephrocalcinosis 121 0.0 67 51.2 77.7 14.0 4.1 0.8 4.1 23.1 . Chronic interstitial nephritis 5,946 1.8 64 49.0 78.6 16.5 2.7 1.2 8.6 18.4 . Acute interstitial nephritis 346 0.1 67 49.4 81.5 15.3 2.0 0.3 2.9 32.1 Hypertensive/large vessel disease 93,651 29.0 69 57.2 58.2 37.5 2.6 0.8 2.1 24.2 . Hypertension, (no primary ren. dis.) 86,403 26.7 68 56.9 55.4 40.2 2.7 0.8 2.2 23.2 . Renal artery stenosis or occlusion 5,894 1.8 72 59.4 92.0 5.9 1.2 0.6 0.7 36.0 . Cholesterol emboli, renal emboli 1,354 0.4 72 66.3 94.0 3.6 1.3 0.6 0.1 36.0 Cystic/Heriditary/Congenital Diseases 11,618 3.6 51 55.9 82.2 13.3 2.3 0.8 19.6 6.5 . Polycystic kidneys, adult (dominant) 8,724 2.7 54 52.3 83.2 12.6 2.4 0.7 16.6 6.5 . Polycystic, infantile (recessive) 65 0.0 22 50.8 75.4 21.5 3.1 0.0 9.2 13.8 . Medullary cystic, inc nephronophthisis 90 0.0 25 58.9 83.3 13.3 1.1 1.1 25.6 4.4 . Alports, other hereditary/familial dis 720 0.2 31 72.1 84.4 10.6 1.8 1.4 29.2 2.6 . Tuberous sclerosis 139 0.0 62 43.9 80.6 15.1 2.2 1.4 5.8 23.7 . Cystinosis 57 0.0 14 59.6 91.2 7.0 0.0 1.8 45.6 3.5 . Primary oxalosis 92 0.0 56 55.4 91.3 6.5 1.1 0.0 17.4 12.0 . Fabrys disease 79 0.0 42 92.4 88.6 7.6 0.0 2.5 21.5 5.1 . Congenital nephrotic syndrome 84 0.0 21 44.0 63.1 25.0 9.5 1.2 16.7 7.1 . Drash syndrome, mesangial sclerosis 11 0.0 44 54.5 54.5 36.4 0.0 9.1 9.1 0.0 . Congenital obstructive uropathy 769 0.2 26 75.2 75.0 17.3 2.9 0.9 28.7 8.8 . Renal hypoplasia, dysplasia 734 0.2 15 58.9 75.7 18.7 1.5 1.5 36.2 4.5 . Prune belly syndrome 54 0.0 12 100.0 75.9 20.4 1.9 0.0 38.9 1.9 Neoplasms/Tumors 5,428 1.7 68 61.8 79.0 18.0 1.5 0.9 0.8 43.6 . Renal or Urological Neoplasms 1,457 0.5 68 70.7 80.6 16.5 1.2 1.0 1.2 36.3 . Multiple myeloma 2,809 0.9 69 59.7 76.5 20.4 1.6 0.9 0.2 49.6 . Light chain nephropathy 158 0.0 71 59.5 75.9 18.4 3.2 0.6 1.3 39.2 . Amyloidosis 1,004 0.3 66 55.4 83.8 13.4 1.5 0.8 1.8 37.9 Miscellaneous Conditions 8,765 2.7 50 66.5 52.2 44.3 1.0 0.8 2.6 35.4 . Complication post bone marr/other txp 111 0.0 53 61.3 84.7 11.7 0.9 1.8 10.8 18.0 . Sickle cell disease/anemia or trait 345 0.1 39 52.2 5.2 92.2 0.0 1.4 1.7 16.5 . AIDS nephropathy 3,264 1.0 38 76.9 9.3 87.7 0.2 0.5 0.1 43.2 . Traumatic/surgical loss of kidney(s) 175 0.1 64 69.1 82.3 12.6 1.7 1.1 2.9 19.4 . Hepatorenal syndrome 329 0.1 56 68.1 85.4 9.1 0.9 2.7 13.4 42.6 . Tubular necrosis (no recovery) 3,188 1.0 68 60.0 84.2 12.9 1.3 0.7 2.4 33.2 . Post-Partum Fail, Oth Renal Disorders 1,353 0.4 66 60.2 78.0 16.8 2.6 1.2 5.9 28.5 Etiology Uncertain 14,151 4.4 65 57.4 70.6 23.2 3.6 1.2 7.2 23.6 Missing 9,175 . 66 50.7 46.6 23.4 1.3 0.6 14.6 36.8 * Values for cells with fewer than 10 patients are suppressed. Includes all patients: residents of the 50 states, the District of Colulmbia, Puerto Rico and the Territories. Table A.16 Incidence Of Reported ESRD Therapy By Detailed Primary Disease And Race For All Patients, 1992-1996 # Native Total # # # Native White Black Asian Amer. Primary Disease Groups Patients White Black Asian Amer. (%) (%) (%) (%) All ESRD, (reference) 332,459 212,461 97,753 10,324 5,044 100.0 100.0 100.0 100.0 Diabetes 130,473 83,729 37,185 4,298 3,188 40.2 38.9 42.1 63.9 . Type 1, juvenile type 46,100 32,377 11,469 1,086 734 15.6 12.0 10.6 14.7 . Type 2, adult-onset or unspec. type 84,373 51,352 25,716 3,212 2,454 24.7 26.9 31.5 49.2 Glomerulonephritis 36,499 24,826 8,789 1,836 452 11.9 9.2 18.0 9.1 . Focal glomerulosclerosis, focal GN 6,497 3,747 2,430 173 62 1.8 2.5 1.7 1.2 . Membranous nephropathy 1,554 1,109 376 36 17 0.5 0.4 0.4 0.3 . Membranoproliferative GN, types 1&2 1,284 953 215 71 22 0.5 0.2 0.7 0.4 . IgA nephropathy, Bergers disease 1,080 799 92 134 20 0.4 0.1 1.3 0.4 . IgM nephropathy 121 86 13 16 * 0.0 0.0 0.2 0.0 . Rapidly progressive GN 1,336 1,071 172 53 20 0.5 0.2 0.5 0.4 . Goodpastures Syndrome 780 697 55 14 * 0.3 0.1 0.1 0.2 . Post infectious GN, SBE 214 161 41 * * 0.1 0.0 0.0 0.1 . Glomerulonephritis (GN) 22,749 15,549 5,230 1,286 287 7.5 5.5 12.6 5.7 . Other proliferative GN 884 654 165 48 10 0.3 0.2 0.5 0.2 Secondary GN/Vasculitis 8,122 5,144 2,482 274 101 2.5 2.6 2.7 2.0 . Lupus erythematosus, (SLE nephritis) 4,177 1,999 1,838 202 46 1.0 1.9 2.0 0.9 . Polyarteritis 173 142 20 * * 0.1 0.0 0.1 0.0 . Wegeners granulomatosis 890 815 48 10 12 0.4 0.1 0.1 0.2 . Henoch-Schonlein syndrome 153 125 11 10 * 0.1 0.0 0.1 0.1 . Vasculitis and its derivatives 467 412 38 * * 0.2 0.0 0.1 0.1 . Scleroderma 740 593 129 * * 0.3 0.1 0.1 0.2 . Hemolytic uremic syndrome 695 573 106 * * 0.3 0.1 0.1 0.1 . Nephropathy from heroin /related abuse 661 388 234 18 13 0.2 0.2 0.2 0.3 . Secondary GN, other 166 97 58 * * 0.0 0.1 0.0 0.1 Interstitial Nephritis/Pyelonephritis 14,577 11,541 2,321 410 139 5.5 2.4 4.0 2.8 . Chronic pyelonephritis, reflux neph. 1,805 1,520 179 63 19 0.7 0.2 0.6 0.4 . Analgesic abuse 416 322 75 10 * 0.2 0.1 0.1 0.1 . Nephropathy caused by other agents 1,865 1,442 350 40 15 0.7 0.4 0.4 0.3 . Nephrolithiasis, Obstruction, Gouty 4,078 3,206 664 124 31 1.5 0.7 1.2 0.6 . Nephrocalcinosis 121 94 17 * * 0.0 0.0 0.0 0.0 . Chronic interstitial nephritis 5,946 4,675 983 161 69 2.2 1.0 1.6 1.4 . Acute interstitial nephritis 346 282 53 * * 0.1 0.1 0.1 0.0 Hypertensive/large vessel disease 93,651 54,542 35,137 2,436 728 26.2 36.8 23.9 14.6 . Hypertension, (no primary ren. dis.) 86,403 47,847 34,740 2,348 684 23.0 36.3 23.0 13.7 . Renal artery stenosis or occlusion 5,894 5,422 348 70 36 2.6 0.4 0.7 0.7 . Cholesterol emboli, renal emboli 1,354 1,273 49 18 * 0.6 0.1 0.2 0.2 Cystic/Heriditary/Congenital Diseases 11,618 9,545 1,548 268 96 4.6 1.6 2.6 1.9 . Polycystic kidneys, adult (dominant) 8,724 7,262 1,103 206 60 3.5 1.2 2.0 1.2 . Polycystic, infantile (recessive) 65 49 14 * 0 0.0 0.0 0.0 0.0 . Medullary cystic, inc nephronophthisis 90 75 12 * * 0.0 0.0 0.0 0.0 . Alports, other hereditary/familial dis 720 608 76 13 10 0.3 0.1 0.1 0.2 . Tuberous sclerosis 139 112 21 * * 0.1 0.0 0.0 0.0 . Cystinosis 57 52 * 0 * 0.0 0.0 0.0 0.0 . Primary oxalosis 92 84 * * 0 0.0 0.0 0.0 0.0 . Fabrys disease 79 70 * 0 * 0.0 0.0 0.0 0.0 . Congenital nephrotic syndrome 84 53 21 * * 0.0 0.0 0.1 0.0 . Drash syndrome, mesangial sclerosis 11 * * 0 * 0.0 0.0 0.0 0.0 . Congenital obstructive uropathy 769 577 133 22 * 0.3 0.1 0.2 0.1 . Renal hypoplasia, dysplasia 734 556 137 11 11 0.3 0.1 0.1 0.2 . Prune belly syndrome 54 41 11 * 0 0.0 0.0 0.0 0.0 Neoplasms/Tumors 5,428 4,286 976 84 48 2.1 1.0 0.8 1.0 . Renal or Urological Neoplasms 1,457 1,175 240 18 15 0.6 0.3 0.2 0.3 . Multiple myeloma 2,809 2,150 572 46 24 1.0 0.6 0.5 0.5 . Light chain nephropathy 158 120 29 * * 0.1 0.0 0.0 0.0 . Amyloidosis 1,004 841 135 15 * 0.4 0.1 0.1 0.2 Miscellaneous Conditions 8,765 4,579 3,881 92 74 2.2 4.1 0.9 1.5 . Complication post bone marr/other txp 111 94 13 * * 0.0 0.0 0.0 0.0 . Sickle cell disease/anemia or trait 345 18 318 0 * 0.0 0.3 0.0 0.1 . AIDS nephropathy 3,264 302 2,861 * 17 0.1 3.0 0.1 0.3 . Traumatic/surgical loss of kidney(s) 175 144 22 * * 0.1 0.0 0.0 0.0 . Hepatorenal syndrome 329 281 30 * * 0.1 0.0 0.0 0.2 . Tubular necrosis (no recovery) 3,188 2,684 410 43 23 1.3 0.4 0.4 0.5 . Post-Partum Fail, Oth Renal Disorders 1,353 1,056 227 35 16 0.5 0.2 0.3 0.3 Etiology Uncertain 14,151 9,994 3,286 506 166 4.8 3.4 5.0 3.3 Missing 9,175 4,275 2,148 120 52 . . . . * Values for cells with fewer than 10 patients are suppressed. Includes all patients: residents of the 50 states, the District of Colulmbia, Puerto Rico and the Territories. Table A.17: Incidence Of Reported ESRD Therapy Median Age At Incidence, Sex, Race, and One Year Transplant and Death Status By Detailed Primary Disease, For Patients Age 65 And Over, 1992-1996 % % Tran % Died Total % Median % % % % Native First First Primary Disease Groups Patients Incid Age Males White Black Asian Amer. Year Year All ESRD, (reference) 155,530 100.0 73 50.8 71.9 22.0 3.0 1.1 0.3 32.4 Diabetes 55,794 37.1 71 42.8 67.3 25.7 3.8 1.9 0.2 30.1 . Type 1, juvenile type 14,571 9.7 71 42.3 71.0 23.8 3.1 1.2 0.2 31.6 . Type 2, adult-onset or unspec. type 41,223 27.4 71 42.9 66.0 26.4 4.1 2.1 0.2 29.6 Glomerulonephritis 12,277 8.2 73 59.4 83.7 11.2 3.7 0.8 0.9 25.6 . Focal glomerulosclerosis, focal GN 1,396 0.9 72 65.1 84.0 12.5 2.5 0.6 1.4 20.6 . Membranous nephropathy 533 0.4 72 63.4 81.8 13.9 3.0 0.6 1.1 18.8 . Membranoproliferative GN, types 1&2 264 0.2 72 58.7 87.5 9.5 1.5 1.1 1.1 19.7 . IgA nephropathy, Bergers disease 148 0.1 71 72.3 88.5 3.4 7.4 0.0 0.0 21.6 . IgM nephropathy 18 0.0 71 83.3 88.9 5.6 5.6 0.0 5.6 5.6 . Rapidly progressive GN 577 0.4 73 50.6 89.9 6.9 1.6 0.9 0.3 30.5 . Goodpastures Syndrome 376 0.2 73 45.2 93.6 4.5 0.8 0.5 0.3 35.9 . Post infectious GN, SBE 70 0.0 74 62.9 91.4 7.1 1.4 0.0 0.0 27.1 . Glomerulonephritis (GN) 8,626 5.7 74 59.3 82.5 11.7 4.3 0.9 0.9 26.2 . Other proliferative GN 269 0.2 72 55.4 87.7 9.3 2.2 0.7 0.0 27.9 Secondary GN/Vasculitis 1,860 1.2 72 44.0 87.1 10.2 1.5 0.8 0.4 35.6 . Lupus erythematosus, (SLE nephritis) 355 0.2 70 25.4 71.0 25.1 2.3 0.3 0.3 32.7 . Polyarteritis 79 0.1 74 40.5 88.6 8.9 1.3 1.3 1.3 29.1 . Wegeners granulomatosis 432 0.3 72 55.8 95.8 2.1 1.2 0.9 0.2 35.6 . Henoch-Schonlein syndrome 14 0.0 73 71.4 92.9 0.0 7.1 0.0 0.0 42.9 . Vasculitis and its derivatives 275 0.2 74 52.4 94.5 3.3 1.1 1.1 0.4 33.8 . Scleroderma 219 0.1 70 23.3 92.7 5.9 0.9 0.5 0.5 48.4 . Hemolytic uremic syndrome 172 0.1 72 34.9 90.1 8.7 0.0 0.6 0.0 39.5 . Nephropathy from heroin /related abuse 264 0.2 74 61.7 79.5 16.3 1.9 1.5 0.4 30.3 . Secondary GN, other 50 0.0 73 54.0 86.0 8.0 6.0 0.0 2.0 34.0 Interstitial Nephritis/Pyelonephritis 7,220 4.8 74 60.0 83.7 12.6 2.4 0.7 0.6 30.7 . Chronic pyelonephritis, reflux neph. 573 0.4 74 36.6 86.4 9.1 3.5 0.7 0.9 30.2 . Analgesic abuse 221 0.1 73 38.5 83.3 12.2 2.7 0.5 0.5 24.0 . Nephropathy caused by other agents 1,018 0.7 74 74.5 80.4 16.1 2.2 0.8 0.4 35.5 . Nephrolithiasis, Obstruction, Gouty 2,294 1.5 75 76.9 82.3 13.9 2.3 0.7 0.3 33.6 . Nephrocalcinosis 64 0.0 76 53.1 79.7 14.1 4.7 0.0 1.6 35.9 . Chronic interstitial nephritis 2,850 1.9 74 48.2 85.4 11.3 2.4 0.7 0.9 26.3 . Acute interstitial nephritis 200 0.1 74 52.0 86.5 10.0 2.5 0.5 0.0 44.0 Hypertensive/large vessel disease 57,302 38.1 74 54.4 71.3 25.1 2.5 0.6 0.2 33.4 . Hypertension, (no primary ren. dis.) 51,365 34.1 75 53.7 68.8 27.5 2.6 0.6 0.2 32.8 . Renal artery stenosis or occlusion 4,814 3.2 74 59.8 93.2 5.0 1.2 0.4 0.1 39.0 . Cholesterol emboli, renal emboli 1,123 0.7 74 65.7 94.9 2.9 1.2 0.4 0.1 39.1 Cystic/Heriditary/Congenital Diseases 2,595 1.7 72 52.0 85.1 11.3 2.4 0.6 1.7 17.3 . Polycystic kidneys, adult (dominant) 2,244 1.5 71 50.6 85.3 11.1 2.5 0.5 1.8 15.6 . Polycystic, infantile (recessive) * 0.0 73 50.0 66.7 33.3 0.0 0.0 0.0 16.7 . Medullary cystic, inc nephronophthisis 13 0.0 73 69.2 76.9 15.4 7.7 0.0 0.0 30.8 . Alports, other hereditary/familial dis 48 0.0 70 43.8 97.9 2.1 0.0 0.0 4.2 12.5 . Tuberous sclerosis 63 0.0 74 55.6 90.5 7.9 0.0 1.6 0.0 38.1 . Cystinosis * 0.0 76 0.0 100.0 0.0 0.0 0.0 0.0 0.0 . Primary oxalosis 29 0.0 70 48.3 89.7 10.3 0.0 0.0 0.0 20.7 . Fabrys disease * 0.0 71 50.0 50.0 50.0 0.0 0.0 0.0 0.0 . Congenital nephrotic syndrome 10 0.0 76 50.0 80.0 10.0 10.0 0.0 0.0 30.0 . Drash syndrome, mesangial sclerosis * 0.0 68 75.0 75.0 25.0 0.0 0.0 0.0 0.0 . Congenital obstructive uropathy 130 0.1 74 74.6 76.2 16.2 3.8 0.8 0.0 32.3 . Renal hypoplasia, dysplasia 43 0.0 73 53.5 81.4 16.3 0.0 2.3 0.0 25.6 . Prune belly syndrome * 0.0 80 100.0 100.0 0.0 0.0 0.0 0.0 50.0 Neoplasms/Tumors 3,341 2.2 73 62.2 82.4 15.3 1.3 0.6 0.0 50.9 . Renal or Urological Neoplasms 877 0.6 74 73.8 83.9 13.6 1.1 1.0 0.1 43.8 . Multiple myeloma 1,819 1.2 73 59.4 80.4 17.3 1.3 0.5 0.0 55.5 . Light chain nephropathy 100 0.1 76 61.0 82.0 15.0 3.0 0.0 0.0 47.0 . Amyloidosis 545 0.4 72 53.0 86.4 11.4 1.5 0.4 0.0 47.3 Miscellaneous Conditions 2,836 1.9 74 60.4 88.2 9.1 1.6 0.7 0.4 41.9 . Complication post bone marr/other txp 20 0.0 67 55.0 95.0 0.0 0.0 5.0 10.0 20.0 . Sickle cell disease/anemia or trait 18 0.0 72 38.9 22.2 77.8 0.0 0.0 0.0 50.0 . AIDS nephropathy 35 0.0 71 65.7 40.0 54.3 2.9 0.0 0.0 40.0 . Traumatic/surgical loss of kidney(s) 86 0.1 74 66.3 87.2 8.1 2.3 1.2 0.0 33.7 . Hepatorenal syndrome 83 0.1 70 68.7 85.5 6.0 0.0 7.2 3.6 63.9 . Tubular necrosis (no recovery) 1,880 1.2 74 57.7 90.4 7.6 1.3 0.4 0.1 41.8 . Post-Partum Fail, Oth Renal Disorders 714 0.5 75 66.4 86.4 9.7 2.5 0.7 0.4 40.9 Etiology Uncertain 7,250 4.8 75 55.8 80.2 15.3 3.1 0.8 0.3 36.3 Missing 5,055 . 73 47.0 42.8 15.1 0.9 0.5 1.5 49.5 * Values for cells with fewer than 10 patients are suppressed. Includes all patients: residents of the 50 states, the District of Colulmbia, Puerto Rico and the Territories. Table A.18: Incidence Of Reported ESRD Therapy By Detailed Primary Disease And Race For Patients Age 65 And Over, 1992-1996 # Native Total # # # Native White Black Asian Amer. Primary Disease Groups Patients White Black Asian Amer. (%) (%) (%) (%) All ESRD, (reference) 155,530 111,817 34,143 4,625 1,699 100.0 100.0 100.0 100.0 Diabetes 55,794 37,568 14,360 2,137 1,040 34.3 43.0 46.6 62.1 . Type 1, juvenile type 14,571 10,346 3,475 458 182 9.4 10.4 10.0 10.9 . Type 2, adult-onset or unspec. type 41,223 27,222 10,885 1,679 858 24.8 32.6 36.7 51.2 Glomerulonephritis 12,277 10,270 1,379 453 102 9.4 4.1 9.9 6.1 . Focal glomerulosclerosis, focal GN 1,396 1,172 174 35 * 1.1 0.5 0.8 0.5 . Membranous nephropathy 533 436 74 16 * 0.4 0.2 0.3 0.2 . Membranoproliferative GN, types 1&2 264 231 25 * * 0.2 0.1 0.1 0.2 . IgA nephropathy, Bergers disease 148 131 * 11 0 0.1 0.0 0.2 0.0 . IgM nephropathy 18 16 * * 0 0.0 0.0 0.0 0.0 . Rapidly progressive GN 577 519 40 * * 0.5 0.1 0.2 0.3 . Goodpastures Syndrome 376 352 17 * * 0.3 0.1 0.1 0.1 . Post infectious GN, SBE 70 64 * * 0 0.1 0.0 0.0 0.0 . Glomerulonephritis (GN) 8,626 7,113 1,013 367 79 6.5 3.0 8.0 4.7 . Other proliferative GN 269 236 25 * * 0.2 0.1 0.1 0.1 Secondary GN/Vasculitis 1,860 1,620 189 28 15 1.5 0.6 0.6 0.9 . Lupus erythematosus, (SLE nephritis) 355 252 89 * * 0.2 0.3 0.2 0.1 . Polyarteritis 79 70 * * * 0.1 0.0 0.0 0.1 . Wegeners granulomatosis 432 414 * * * 0.4 0.0 0.1 0.2 . Henoch-Schonlein syndrome 14 13 0 * 0 0.0 0.0 0.0 0.0 . Vasculitis and its derivatives 275 260 * * * 0.2 0.0 0.1 0.2 . Scleroderma 219 203 13 * * 0.2 0.0 0.0 0.1 . Hemolytic uremic syndrome 172 155 15 0 * 0.1 0.0 0.0 0.1 . Nephropathy from heroin /related abuse 264 210 43 * * 0.2 0.1 0.1 0.2 . Secondary GN, other 50 43 * * 0 0.0 0.0 0.1 0.0 Interstitial Nephritis/Pyelonephritis 7,220 6,042 912 175 48 5.5 2.7 3.8 2.9 . Chronic pyelonephritis, reflux neph. 573 495 52 20 * 0.5 0.2 0.4 0.2 . Analgesic abuse 221 184 27 * * 0.2 0.1 0.1 0.1 . Nephropathy caused by other agents 1,018 818 164 22 * 0.7 0.5 0.5 0.5 . Nephrolithiasis, Obstruction, Gouty 2,294 1,888 319 52 15 1.7 1.0 1.1 0.9 . Nephrocalcinosis 64 51 * * 0 0.0 0.0 0.1 0.0 . Chronic interstitial nephritis 2,850 2,433 321 67 19 2.2 1.0 1.5 1.1 . Acute interstitial nephritis 200 173 20 * * 0.2 0.1 0.1 0.1 Hypertensive/large vessel disease 57,302 40,876 14,377 1,409 353 37.3 43.1 30.8 21.1 . Hypertension, (no primary ren. dis.) 51,365 35,322 14,104 1,338 328 32.2 42.3 29.2 19.6 . Renal artery stenosis or occlusion 4,814 4,488 240 57 20 4.1 0.7 1.2 1.2 . Cholesterol emboli, renal emboli 1,123 1,066 33 14 * 1.0 0.1 0.3 0.3 Cystic/Heriditary/Congenital Diseases 2,595 2,208 292 62 15 2.0 0.9 1.4 0.9 . Polycystic kidneys, adult (dominant) 2,244 1,915 248 55 12 1.7 0.7 1.2 0.7 . Polycystic, infantile (recessive) * * * 0 0 0.0 0.0 0.0 0.0 . Medullary cystic, inc nephronophthisis 13 10 * * 0 0.0 0.0 0.0 0.0 . Alports, other hereditary/familial dis 48 47 * 0 0 0.0 0.0 0.0 0.0 . Tuberous sclerosis 63 57 * 0 * 0.1 0.0 0.0 0.1 . Cystinosis * * 0 0 0 0.0 0.0 0.0 0.0 . Primary oxalosis 29 26 * 0 0 0.0 0.0 0.0 0.0 . Fabrys disease * * * 0 0 0.0 0.0 0.0 0.0 . Congenital nephrotic syndrome 10 * * * 0 0.0 0.0 0.0 0.0 . Drash syndrome, mesangial sclerosis * * * 0 0 0.0 0.0 0.0 0.0 . Congenital obstructive uropathy 130 99 21 * * 0.1 0.1 0.1 0.1 . Renal hypoplasia, dysplasia 43 35 * 0 * 0.0 0.0 0.0 0.1 . Prune belly syndrome * * 0 0 0 0.0 0.0 0.0 0.0 Neoplasms/Tumors 3,341 2,752 510 45 21 2.5 1.5 1.0 1.3 . Renal or Urological Neoplasms 877 736 119 10 * 0.7 0.4 0.2 0.5 . Multiple myeloma 1,819 1,463 314 24 10 1.3 0.9 0.5 0.6 . Light chain nephropathy 100 82 15 * 0 0.1 0.0 0.1 0.0 . Amyloidosis 545 471 62 * * 0.4 0.2 0.2 0.1 Miscellaneous Conditions 2,836 2,500 257 46 20 2.3 0.8 1.0 1.2 . Complication post bone marr/other txp 20 19 0 0 * 0.0 0.0 0.0 0.1 . Sickle cell disease/anemia or trait 18 * 14 0 0 0.0 0.0 0.0 0.0 . AIDS nephropathy 35 14 19 * 0 0.0 0.1 0.0 0.0 . Traumatic/surgical loss of kidney(s) 86 75 * * * 0.1 0.0 0.0 0.1 . Hepatorenal syndrome 83 71 * 0 * 0.1 0.0 0.0 0.4 . Tubular necrosis (no recovery) 1,880 1,700 143 25 * 1.6 0.4 0.5 0.4 . Post-Partum Fail, Oth Renal Disorders 714 617 69 18 * 0.6 0.2 0.4 0.3 Etiology Uncertain 7,250 5,815 1,106 226 61 5.3 3.3 4.9 3.6 Missing 5,055 2,166 761 44 24 . . . . * Values for cells with fewer than 10 patients are suppressed. Includes all patients: residents of the 50 states, the District of Colulmbia, Puerto Rico and the Territories. Table A.19: Incidence Of Reported ESRD Therapy Median Age At Incidence, Sex, Race, and One Year Transplant and Death Status By Detailed Primary Disease, For Adult Patients Age 20-64, 1992-1996 % % Tran % Died Total % Median % % % % Native First First Primary Disease Groups Patients Incid Age Males White Black Asian Amer. Year Year All ESRD, (reference) 171,774 100.0 51 55.3 56.7 36.2 3.2 1.9 8.7 12.1 Diabetes 74,596 44.4 54 50.8 61.8 30.6 2.9 2.9 6.2 13.6 . Type 1, juvenile type 31,487 18.7 49 52.6 69.9 25.3 2.0 1.8 10.5 13.5 . Type 2, adult-onset or unspec. Type 43,109 25.7 56 49.5 55.9 34.4 3.6 3.7 3.0 13.6 Glomerulonephritis 22,587 13.4 44 62.0 60.3 30.4 5.8 1.4 15.3 5.8 . Focal glomerulosclerosis, focal GN 4,586 2.7 41 62.3 51.2 43.9 2.6 1.1 15.7 5.3 . Membranous nephropathy 998 0.6 49 68.5 66.5 28.9 2.0 1.4 16.0 5.2 . Membranoproliferative GN, types 1&2 890 0.5 42 63.1 71.1 18.1 7.0 1.9 20.1 5.5 . IgA nephropathy, Bergers disease 866 0.5 39 69.1 71.8 9.1 13.9 1.7 21.5 2.0 . IgM nephropathy 97 0.1 39 64.9 69.1 9.3 15.5 1.0 32.0 3.1 . Rapidly progressive GN 653 0.4 47 55.3 73.2 18.4 5.4 1.4 12.7 4.6 . Goodpastures Syndrome 370 0.2 49 49.2 85.1 9.5 2.7 1.9 10.8 14.9 . Post infectious GN, SBE 137 0.1 44 62.0 67.2 24.8 2.9 2.9 11.7 7.3 . Glomerulonephritis (GN) 13,440 8.0 44 61.7 59.8 29.8 6.5 1.5 14.6 6.1 . Other proliferative GN 550 0.3 44 57.8 68.2 22.4 6.9 1.5 17.8 7.1 Secondary GN/Vasculitis 5,792 3.4 41 29.1 55.8 37.4 3.7 1.4 8.5 12.4 . Lupus erythematosus, (SLE nephritis) 3,565 2.1 37 18.5 45.7 46.2 4.8 1.2 9.6 9.3 . Polyarteritis 87 0.1 47 60.9 78.2 13.8 5.7 1.1 6.9 18.4 . Wegeners granulomatosis 430 0.3 54 64.9 87.7 8.6 1.2 1.9 8.1 12.6 . Henoch-Schonlein syndrome 89 0.1 32 56.2 75.3 12.4 7.9 4.5 23.6 5.6 . Vasculitis and its derivatives 185 0.1 53 42.7 80.5 13.5 1.6 1.6 5.4 17.3 . Scleroderma 520 0.3 50 23.5 75.0 22.1 1.2 1.3 3.1 27.9 . Hemolytic uremic syndrome 424 0.3 45 32.3 79.0 19.3 1.2 0.5 5.0 15.3 . Nephropathy from heroin /related abuse 380 0.2 44 63.4 44.5 49.2 2.6 2.4 10.3 13.7 . Secondary GN, other 112 0.1 43 57.1 44.6 48.2 0.0 3.6 3.6 16.1 Interstitial Nephritis/Pyelonephritis 6,799 4.0 48 52.7 74.6 19.3 3.2 1.3 12.9 10.9 . Chronic pyelonephritis, reflux neph. 1,112 0.7 42 38.0 83.5 10.1 3.6 1.3 17.8 5.6 . Analgesic abuse 193 0.1 53 31.6 70.5 24.9 2.1 1.0 4.7 10.4 . Nephropathy caused by other agents 776 0.5 51 65.7 72.9 22.7 2.3 0.8 9.8 15.7 . Nephrolithiasis, Obstruction, Gouty 1,553 0.9 51 65.9 73.7 19.2 4.3 1.0 10.5 11.1 . Nephrocalcinosis 56 0.0 51 50.0 75.0 14.3 3.6 1.8 7.1 8.9 . Chronic interstitial nephritis 2,973 1.8 48 49.6 72.4 21.6 2.9 1.6 14.2 11.3 . Acute interstitial nephritis 136 0.1 53 44.1 76.5 20.6 1.5 0.0 5.1 16.9 Hypertensive/large vessel disease 36,091 21.5 51 61.5 37.6 57.1 2.8 1.0 4.9 9.7 . Hypertension, (no primary ren. dis.) 34,801 20.7 51 61.6 35.8 58.9 2.9 1.0 5.0 9.2 . Renal artery stenosis or occlusion 1,059 0.6 60 58.1 86.7 9.9 1.2 1.4 3.1 23.3 . Cholesterol emboli, renal emboli 231 0.1 61 69.3 89.6 6.9 1.7 1.3 0.4 20.8 Cystic/Heriditary/Congenital Diseases 7,764 4.6 48 55.4 82.7 13.1 2.2 0.8 21.7 3.5 . Polycystic kidneys, adult (dominant) 6,352 3.8 50 53.0 82.6 13.2 2.3 0.7 21.2 3.3 . Polycystic, infantile (recessive) 28 0.0 43 60.7 78.6 21.4 0.0 0.0 14.3 17.9 . Medullary cystic, inc nephronophthisis 37 0.0 33 59.5 83.8 13.5 0.0 0.0 24.3 0.0 . Alports, other hereditary/familial dis 523 0.3 34 70.7 87.2 8.2 1.7 1.0 28.1 2.3 . Tuberous sclerosis 73 0.0 47 32.9 74.0 20.5 2.7 1.4 9.6 12.3 . Cystinosis 17 0.0 43 58.8 88.2 5.9 0.0 5.9 11.8 11.8 . Primary oxalosis 50 0.0 53 58.0 94.0 4.0 0.0 0.0 20.0 10.0 . Fabrys disease 76 0.0 42 93.4 89.5 6.6 0.0 2.6 22.4 5.3 . Congenital nephrotic syndrome 33 0.0 36 48.5 54.5 36.4 9.1 0.0 21.2 0.0 . Drash syndrome, mesangial sclerosis * 0.0 44 33.3 0.0 66.7 0.0 33.3 0.0 0.0 . Congenital obstructive uropathy 343 0.2 35 70.6 79.3 15.7 2.6 1.2 21.3 5.5 . Renal hypoplasia, dysplasia 219 0.1 33 55.7 82.2 15.5 0.5 0.5 26.9 1.8 . Prune belly syndrome 10 0.0 26 100.0 80.0 20.0 0.0 0.0 10.0 0.0 Neoplasms/Tumors 2,055 1.2 56 61.5 73.6 22.3 1.8 1.2 1.8 32.1 . Renal or Urological Neoplasms 549 0.3 56 66.8 76.3 20.8 1.3 0.7 2.2 25.3 . Multiple myeloma 990 0.6 57 60.2 69.4 26.1 2.2 1.4 0.6 38.7 . Light chain nephropathy 58 0.0 56 56.9 65.5 24.1 3.4 1.7 3.4 25.9 . Amyloidosis 458 0.3 55 58.3 80.6 15.9 1.5 1.3 3.9 26.9 Miscellaneous Conditions 5,783 3.4 41 69.7 34.6 61.7 0.8 0.9 3.1 33.0 . Complication post bone marr/other txp 90 0.1 50 62.2 82.2 14.4 1.1 1.1 10.0 17.8 . Sickle cell disease/anemia or trait 312 0.2 39 52.2 4.2 92.9 0.0 1.6 1.3 15.4 . AIDS nephropathy 3,211 1.9 38 77.0 8.9 88.0 0.2 0.5 0.1 43.4 . Traumatic/surgical loss of kidney(s) 84 0.1 45 73.8 78.6 16.7 1.2 1.2 6.0 6.0 . Hepatorenal syndrome 244 0.1 52 67.6 85.7 9.8 1.2 1.2 16.4 35.7 . Tubular necrosis (no recovery) 1,258 0.7 53 63.8 75.4 20.3 1.4 1.3 5.0 21.4 . Post-Partum Fail, Oth Renal Disorders 584 0.3 49 53.3 69.2 24.7 2.9 1.5 9.8 15.2 Etiology Uncertain 6,483 3.9 47 59.6 60.3 32.0 4.1 1.5 12.8 10.8 Missing 3,824 . 50 54.9 50.6 34.1 1.9 0.7 27.8 22.6 * Values for cells with fewer than 10 patients are suppressed. Includes all patients: residents of the 50 states, the District of Colulmbia, Puerto Rico and the Territories. Table A.20: Incidence Of Reported ESRD Therapy By Detailed Primary Disease And Race For Adult Patients Age 20-64, 1992-1996 # Native Total # # # Native White Black Asian Amer. Primary Disease Groups Patients White Black Asian Amer. (%) (%) (%) (%) All ESRD, (reference) 171,774 97,394 62,196 5,495 3,266 100.0 100.0 100.0 100.0 Diabetes 74,596 46,116 22,797 2,157 2,146 48.3 37.4 39.8 66.3 . Type 1, juvenile type 31,487 22,009 7,978 626 552 23.1 13.1 11.5 17.0 . Type 2, adult-onset or unspec. type 43,109 24,107 14,819 1,531 1,594 25.3 24.3 28.2 49.2 Glomerulonephritis 22,587 13,625 6,873 1,299 320 14.3 11.3 23.9 9.9 . Focal glomerulosclerosis, focal GN 4,586 2,346 2,014 120 49 2.5 3.3 2.2 1.5 . Membranous nephropathy 998 664 288 20 14 0.7 0.5 0.4 0.4 . Membranoproliferative GN, types 1&2 890 633 161 62 17 0.7 0.3 1.1 0.5 . IgA nephropathy, Bergers disease 866 622 79 120 15 0.7 0.1 2.2 0.5 . IgM nephropathy 97 67 * 15 * 0.1 0.0 0.3 0.0 . Rapidly progressive GN 653 478 120 35 * 0.5 0.2 0.6 0.3 . Goodpastures Syndrome 370 315 35 10 * 0.3 0.1 0.2 0.2 . Post infectious GN, SBE 137 92 34 * * 0.1 0.1 0.1 0.1 . Glomerulonephritis (GN) 13,440 8,033 4,010 875 196 8.4 6.6 16.1 6.1 . Other proliferative GN 550 375 123 38 * 0.4 0.2 0.7 0.2 Secondary GN/Vasculitis 5,792 3,234 2,169 213 81 3.4 3.6 3.9 2.5 . Lupus erythematosus, (SLE nephritis) 3,565 1,629 1,646 172 43 1.7 2.7 3.2 1.3 . Polyarteritis 87 68 12 * * 0.1 0.0 0.1 0.0 . Wegeners granulomatosis 430 377 37 * * 0.4 0.1 0.1 0.2 . Henoch-Schonlein syndrome 89 67 11 * * 0.1 0.0 0.1 0.1 . Vasculitis and its derivatives 185 149 25 * * 0.2 0.0 0.1 0.1 . Scleroderma 520 390 115 * * 0.4 0.2 0.1 0.2 . Hemolytic uremic syndrome 424 335 82 * * 0.4 0.1 0.1 0.1 . Nephropathy from heroin /related abuse 380 169 187 10 * 0.2 0.3 0.2 0.3 . Secondary GN, other 112 50 54 0 * 0.1 0.1 0.0 0.1 Interstitial Nephritis/Pyelonephritis 6,799 5,074 1,312 219 87 5.3 2.2 4.0 2.7 . Chronic pyelonephritis, reflux neph. 1,112 929 112 40 15 1.0 0.2 0.7 0.5 . Analgesic abuse 193 136 48 * * 0.1 0.1 0.1 0.1 . Nephropathy caused by other agents 776 566 176 18 * 0.6 0.3 0.3 0.2 . Nephrolithiasis, Obstruction, Gouty 1,553 1,145 298 67 15 1.2 0.5 1.2 0.5 . Nephrocalcinosis 56 42 * * * 0.0 0.0 0.0 0.0 . Chronic interstitial nephritis 2,973 2,152 642 86 48 2.3 1.1 1.6 1.5 . Acute interstitial nephritis 136 104 28 * 0 0.1 0.0 0.0 0.0 Hypertensive/large vessel disease 36,091 13,567 20,624 1,019 368 14.2 33.9 18.8 11.4 . Hypertension, (no primary ren. dis.) 34,801 12,442 20,503 1,002 350 13.0 33.7 18.5 10.8 . Renal artery stenosis or occlusion 1,059 918 105 13 15 1.0 0.2 0.2 0.5 . Cholesterol emboli, renal emboli 231 207 16 * * 0.2 0.0 0.1 0.1 Cystic/Heriditary/Congenital Diseases 7,764 6,420 1,017 168 61 6.7 1.7 3.1 1.9 . Polycystic kidneys, adult (dominant) 6,352 5,249 836 144 46 5.5 1.4 2.7 1.4 . Polycystic, infantile (recessive) 28 22 * 0 0 0.0 0.0 0.0 0.0 . Medullary cystic, inc nephronophthisis 37 31 * 0 0 0.0 0.0 0.0 0.0 . Alports, other hereditary/familial dis 523 456 43 * * 0.5 0.1 0.2 0.2 . Tuberous sclerosis 73 54 15 * * 0.1 0.0 0.0 0.0 . Cystinosis 17 15 * 0 * 0.0 0.0 0.0 0.0 . Primary oxalosis 50 47 * 0 0 0.0 0.0 0.0 0.0 . Fabrys disease 76 68 * 0 * 0.1 0.0 0.0 0.1 . Congenital nephrotic syndrome 33 18 12 * 0 0.0 0.0 0.1 0.0 . Drash syndrome, mesangial sclerosis * 0 * 0 * 0.0 0.0 0.0 0.0 . Congenital obstructive uropathy 343 272 54 * * 0.3 0.1 0.2 0.1 . Renal hypoplasia, dysplasia 219 180 34 * * 0.2 0.1 0.0 0.0 . Prune belly syndrome 10 * * 0 0 0.0 0.0 0.0 0.0 Neoplasms/Tumors 2,055 1,513 459 38 25 1.6 0.8 0.7 0.8 . Renal or Urological Neoplasms 549 419 114 * * 0.4 0.2 0.1 0.1 . Multiple myeloma 990 687 258 22 14 0.7 0.4 0.4 0.4 . Light chain nephropathy 58 38 14 * * 0.0 0.0 0.0 0.0 . Amyloidosis 458 369 73 * * 0.4 0.1 0.1 0.2 Miscellaneous Conditions 5,783 2,001 3,568 45 52 2.1 5.9 0.8 1.6 . Complication post bone marr/other txp 90 74 13 * * 0.1 0.0 0.0 0.0 . Sickle cell disease/anemia or trait 312 13 290 0 * 0.0 0.5 0.0 0.2 . AIDS nephropathy 3,211 286 2,827 * 17 0.3 4.6 0.1 0.5 . Traumatic/surgical loss of kidney(s) 84 66 14 * * 0.1 0.0 0.0 0.0 . Hepatorenal syndrome 244 209 24 * * 0.2 0.0 0.1 0.1 . Tubular necrosis (no recovery) 1,258 949 256 17 16 1.0 0.4 0.3 0.5 . Post-Partum Fail, Oth Renal Disorders 584 404 144 17 * 0.4 0.2 0.3 0.3 Etiology Uncertain 6,483 3,909 2,072 266 99 4.1 3.4 4.9 3.1 Missing 3,824 1,935 1,305 71 27 . . . . * Values for cells with fewer than 10 patients are suppressed. Includes all patients: residents of the 50 states, the District of Colulmbia, Puerto Rico and the Territories. Table A.21: Incidence Of Reported ESRD Therapy Median Age At Incidence, Sex, Race, and One Year Transplant and Death Status By Detailed Primary Disease, For Pediatric Patients Age < 20, 1992-1996 % % Tran % Died Total % Median % % % % Native First First Primary Disease Groups Patients Incid Age Males White Black Asian Amer. Year Year All ESRD, (reference) 5,155 100.0 14 57.1 63.0 27.4 4.0 1.5 37.3 2.9 Diabetes 83 1.7 16 39.8 54.2 33.7 4.8 2.4 13.3 2.4 . Type 1, juvenile type 42 0.9 18 40.5 52.4 38.1 4.8 0.0 23.8 2.4 . Type 2, adult-onset or unspec. type 41 0.8 3 39.0 56.1 29.3 4.9 4.9 2.4 2.4 Glomerulonephritis 1,635 33.6 16 55.0 56.9 32.8 5.1 1.8 33.3 1.6 . Focal glomerulosclerosis, focal GN 515 10.6 16 60.2 44.5 47.0 3.5 1.0 30.9 1.2 . Membranous nephropathy 23 0.5 16 52.2 39.1 60.9 0.0 0.0 13.0 4.3 . Membranoproliferative GN, types 1&2 130 2.7 15 45.4 68.5 22.3 3.8 1.5 36.9 0.0 . IgA nephropathy, Bergers disease 66 1.4 17 71.2 69.7 12.1 4.5 7.6 28.8 0.0 . IgM nephropathy * 0.1 19 33.3 50.0 50.0 0.0 0.0 33.3 0.0 . Rapidly progressive GN 106 2.2 14 39.6 69.8 11.3 8.5 5.7 33.0 0.9 . Goodpastures Syndrome 34 0.7 16 47.1 88.2 8.8 2.9 0.0 17.6 2.9 . Post infectious GN, SBE * 0.1 15 42.9 71.4 28.6 0.0 0.0 28.6 14.3 . Glomerulonephritis (GN) 683 14.1 16 54.8 59.0 30.3 6.4 1.8 36.5 2.0 . Other proliferative GN 65 1.3 16 53.8 66.2 26.2 6.2 0.0 33.8 3.1 Secondary GN/Vasculitis 470 9.7 16 36.6 61.7 26.4 7.0 1.1 21.1 5.5 . Lupus erythematosus, (SLE nephritis) 257 5.3 17 24.5 45.9 40.1 8.6 0.8 10.1 7.0 . Polyarteritis * 0.1 14 0.0 57.1 14.3 28.6 0.0 42.9 28.6 . Wegeners granulomatosis 28 0.6 17 50.0 85.7 7.1 0.0 0.0 17.9 7.1 . Henoch-Schonlein syndrome 50 1.0 14 52.0 90.0 0.0 4.0 2.0 42.0 2.0 . Vasculitis and its derivatives * 0.1 18 42.9 42.9 57.1 0.0 0.0 14.3 0.0 . Scleroderma * 0.0 17 0.0 0.0 100.0 0.0 0.0 0.0 0.0 . Hemolytic uremic syndrome 99 2.0 9 57.6 83.8 9.1 4.0 2.0 34.3 3.0 . Nephropathy from heroin /related abuse 17 0.3 13 47.1 52.9 23.5 17.6 0.0 47.1 0.0 . Secondary GN, other * 0.1 12 25.0 100.0 0.0 0.0 0.0 25.0 0.0 Interstitial Nephritis/Pyelonephritis 558 11.5 14 63.3 76.2 17.4 2.9 0.7 45.2 2.5 . Chronic pyelonephritis, reflux neph. 120 2.5 16 44.2 80.0 12.5 2.5 0.0 33.3 0.8 . Analgesic abuse * 0.0 18 50.0 100.0 0.0 0.0 0.0 0.0 0.0 . Nephropathy caused by other agents 71 1.5 14 69.0 81.7 14.1 0.0 1.4 43.7 2.8 . Nephrolithiasis, Obstruction, Gouty 231 4.8 12 76.2 74.9 20.3 2.2 0.4 49.8 2.2 . Nephrocalcinosis * 0.0 15 0.0 100.0 0.0 0.0 0.0 0.0 0.0 . Chronic interstitial nephritis 123 2.5 15 54.5 73.2 16.3 6.5 1.6 51.2 4.9 . Acute interstitial nephritis 10 0.2 17 70.0 50.0 50.0 0.0 0.0 30.0 0.0 Hypertensive/large vessel disease 258 5.3 17 57.8 38.4 52.7 3.1 2.7 25.6 4.7 . Hypertension, (no primary ren. dis.) 237 4.9 17 58.6 35.0 56.1 3.4 2.5 24.9 4.6 . Renal artery stenosis or occlusion 21 0.4 9 47.6 76.2 14.3 0.0 4.8 33.3 4.8 . Cholesterol emboli, renal emboli 0 . . . . . . . . . Cystic/Heriditary/Congenital Diseases 1,259 25.9 11 66.8 72.8 19.0 3.0 1.6 43.7 2.9 . Polycystic kidneys, adult (dominant) 128 2.6 10 44.5 76.6 14.8 5.5 1.6 46.1 3.1 . Polycystic, infantile (recessive) 31 0.6 3 41.9 74.2 19.4 6.5 0.0 6.5 9.7 . Medullary cystic, inc nephronophthisis 40 0.8 13 55.0 85.0 12.5 0.0 2.5 35.0 0.0 . Alports, other hereditary/familial dis 149 3.1 16 85.9 70.5 21.5 2.7 3.4 40.9 0.7 . Tuberous sclerosis * 0.1 17 66.7 33.3 33.3 33.3 0.0 33.3 0.0 . Cystinosis 39 0.8 12 61.5 92.3 7.7 0.0 0.0 61.5 0.0 . Primary oxalosis 13 0.3 0 61.5 84.6 7.7 7.7 0.0 46.2 0.0 . Fabrys disease * 0.0 19 100.0 100.0 0.0 0.0 0.0 0.0 0.0 . Congenital nephrotic syndrome 41 0.8 1 39.0 65.9 19.5 9.8 2.4 17.1 7.3 . Drash syndrome, mesangial sclerosis * 0.1 1 50.0 75.0 25.0 0.0 0.0 25.0 0.0 . Congenital obstructive uropathy 296 6.1 11 80.7 69.6 19.6 2.7 0.7 50.0 2.4 . Renal hypoplasia, dysplasia 472 9.7 8 60.8 72.2 20.3 2.1 1.9 43.9 3.8 . Prune belly syndrome 42 0.9 10 100.0 73.8 21.4 2.4 0.0 47.6 0.0 Neoplasms/Tumors 32 0.7 6 50.0 65.6 21.9 3.1 6.3 15.6 18.8 . Renal or Urological Neoplasms 31 0.6 6 51.6 64.5 22.6 3.2 6.5 16.1 19.4 . Multiple myeloma 0 . . . . . . . . . . Light chain nephropathy 0 . . . . . . . . . . Amyloidosis * 0.0 11 0.0 100.0 0.0 0.0 0.0 0.0 0.0 Miscellaneous Conditions 146 3.0 13 58.2 53.4 38.4 0.7 1.4 23.3 7.5 . Complication post bone marr/other txp * 0.0 17 100.0 100.0 0.0 0.0 0.0 100.0 0.0 . Sickle cell disease/anemia or trait 15 0.3 16 66.7 6.7 93.3 0.0 0.0 13.3 0.0 . AIDS nephropathy 18 0.4 16 72.2 11.1 83.3 0.0 0.0 0.0 22.2 . Traumatic/surgical loss of kidney(s) * 0.1 13 40.0 60.0 20.0 0.0 0.0 0.0 0.0 . Hepatorenal syndrome * 0.0 13 100.0 50.0 50.0 0.0 0.0 50.0 0.0 . Tubular necrosis (no recovery) 50 1.0 10 54.0 70.0 22.0 2.0 0.0 20.0 6.0 . Post-Partum Fail, Oth Renal Disorders 55 1.1 13 54.5 63.6 25.5 0.0 3.6 36.4 7.3 Etiology Uncertain 418 8.6 15 51.7 64.6 25.8 3.3 1.4 39.5 1.9 Missing 296 . 13 60.5 58.8 27.7 1.7 0.3 66.9 3.4 * Values for cells with fewer than 10 patients are suppressed. Includes all patients: residents of the 50 states, the District of Colulmbia, Puerto Rico and the Territories. Table A.22: Incidence Of Reported ESRD Therapy By Detailed Primary Disease And Race For Pediatric Patients Age < 20, 1992-1996 # Native Total # # # Native White Black Asian Amer. Primary Disease Groups Patients White Black Asian Amer. (%) (%) (%) (%) All ESRD, (reference) 5,155 3,250 1,414 204 79 100.0 100.0 100.0 100.0 Diabetes 83 45 28 * * 1.5 2.1 2.0 2.6 . Type 1, juvenile type 42 22 16 * 0 0.7 1.2 1.0 0.0 . Type 2, adult-onset or unspec. type 41 23 12 * * 0.7 0.9 1.0 2.6 Glomerulonephritis 1,635 931 537 84 30 30.3 40.3 42.2 38.5 . Focal glomerulosclerosis, focal GN 515 229 242 18 * 7.4 18.2 9.0 6.4 . Membranous nephropathy 23 * 14 0 0 0.3 1.1 0.0 0.0 . Membranoproliferative GN, types 1&2 130 89 29 * * 2.9 2.2 2.5 2.6 . IgA nephropathy, Bergers disease 66 46 * * * 1.5 0.6 1.5 6.4 . IgM nephropathy * * * 0 0 0.1 0.2 0.0 0.0 . Rapidly progressive GN 106 74 12 * * 2.4 0.9 4.5 7.7 . Goodpastures Syndrome 34 30 * * 0 1.0 0.2 0.5 0.0 . Post infectious GN, SBE * * * 0 0 0.2 0.2 0.0 0.0 . Glomerulonephritis (GN) 683 403 207 44 12 13.1 15.5 22.1 15.4 . Other proliferative GN 65 43 17 * 0 1.4 1.3 2.0 0.0 Secondary GN/Vasculitis 470 290 124 33 * 9.4 9.3 16.6 6.4 . Lupus erythematosus, (SLE nephritis) 257 118 103 22 * 3.8 7.7 11.1 2.6 . Polyarteritis * * * * 0 0.1 0.1 1.0 0.0 . Wegeners granulomatosis 28 24 * 0 0 0.8 0.2 0.0 0.0 . Henoch-Schonlein syndrome 50 45 0 * * 1.5 0.0 1.0 1.3 . Vasculitis and its derivatives * * * 0 0 0.1 0.3 0.0 0.0 . Scleroderma * 0 * 0 0 0.0 0.1 0.0 0.0 . Hemolytic uremic syndrome 99 83 * * * 2.7 0.7 2.0 2.6 . Nephropathy from heroin /related abuse 17 * * * 0 0.3 0.3 1.5 0.0 . Secondary GN, other * * 0 0 0 0.1 0.0 0.0 0.0 Interstitial Nephritis/Pyelonephritis 558 425 97 16 * 13.8 7.3 8.0 5.1 . Chronic pyelonephritis, reflux neph. 120 96 15 * 0 3.1 1.1 1.5 0.0 . Analgesic abuse * * 0 0 0 0.1 0.0 0.0 0.0 . Nephropathy caused by other agents 71 58 10 0 * 1.9 0.8 0.0 1.3 . Nephrolithiasis, Obstruction, Gouty 231 173 47 * * 5.6 3.5 2.5 1.3 . Nephrocalcinosis * * 0 0 0 0.0 0.0 0.0 0.0 . Chronic interstitial nephritis 123 90 20 * * 2.9 1.5 4.0 2.6 . Acute interstitial nephritis 10 * * 0 0 0.2 0.4 0.0 0.0 Hypertensive/large vessel disease 258 99 136 * * 3.2 10.2 4.0 9.0 . Hypertension, (no primary ren. dis.) 237 83 133 * * 2.7 10.0 4.0 7.7 . Renal artery stenosis or occlusion 21 16 * 0 * 0.5 0.2 0.0 1.3 . Cholesterol emboli, renal emboli 0 0 0 0 0 . . . . Cystic/Heriditary/Congenital Diseases 1,259 917 239 38 20 29.8 17.9 19.1 25.6 . Polycystic kidneys, adult (dominant) 128 98 19 * * 3.2 1.4 3.5 2.6 . Polycystic, infantile (recessive) 31 23 * * 0 0.7 0.5 1.0 0.0 . Medullary cystic, inc nephronophthisis 40 34 * 0 * 1.1 0.4 0.0 1.3 . Alports, other hereditary/familial dis 149 105 32 * * 3.4 2.4 2.0 6.4 . Tuberous sclerosis * * * * 0 0.0 0.1 0.5 0.0 . Cystinosis 39 36 * 0 0 1.2 0.2 0.0 0.0 . Primary oxalosis 13 11 * * 0 0.4 0.1 0.5 0.0 . Fabrys disease * * 0 0 0 0.0 0.0 0.0 0.0 . Congenital nephrotic syndrome 41 27 * * * 0.9 0.6 2.0 1.3 . Drash syndrome, mesangial sclerosis * * * 0 0 0.1 0.1 0.0 0.0 . Congenital obstructive uropathy 296 206 58 * * 6.7 4.4 4.0 2.6 . Renal hypoplasia, dysplasia 472 341 96 10 * 11.1 7.2 5.0 11.5 . Prune belly syndrome 42 31 * * 0 1.0 0.7 0.5 0.0 Neoplasms/Tumors 32 21 * * * 0.7 0.5 0.5 2.6 . Renal or Urological Neoplasms 31 20 * * * 0.7 0.5 0.5 2.6 . Multiple myeloma 0 0 0 0 0 . . . . . Light chain nephropathy 0 0 0 0 0 . . . . . Amyloidosis * * 0 0 0 0.0 0.0 0.0 0.0 Miscellaneous Conditions 146 78 56 * * 2.5 4.2 0.5 2.6 . Complication post bone marr/other txp * * 0 0 0 0.0 0.0 0.0 0.0 . Sickle cell disease/anemia or trait 15 * 14 0 0 0.0 1.1 0.0 0.0 . AIDS nephropathy 18 * 15 0 0 0.1 1.1 0.0 0.0 . Traumatic/surgical loss of kidney(s) * * * 0 0 0.1 0.1 0.0 0.0 . Hepatorenal syndrome * * * 0 0 0.0 0.1 0.0 0.0 . Tubular necrosis (no recovery) 50 35 11 * 0 1.1 0.8 0.5 0.0 . Post-Partum Fail, Oth Renal Disorders 55 35 14 0 * 1.1 1.1 0.0 2.6 Etiology Uncertain 418 270 108 14 * 8.8 8.1 7.0 7.7 Missing 296 174 82 * * . . . . * Values for cells with fewer than 10 patients are suppressed. Includes all patients: residents of the 50 states, the District of Colulmbia, Puerto Rico and the Territories. Table A.23 Incidence Counts of Reported ESRD Therapy By State After Dropping Territories and Unknown States Year 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 State Alabama 644 751 947 847 1,015 1,134 1,092 1,233 1,361 1,432 Alaska 28 36 47 36 49 58 53 208 378 69 Arizona 508 570 669 695 784 960 920 1,093 1,166 1,229 Arkansas 348 377 379 411 501 523 560 673 728 705 California 3,919 4,313 4,988 5,390 5,841 5,939 6,210 7,548 8,009 7,861 Colorado 312 309 400 403 465 504 506 548 548 643 Connecticut 495 467 549 603 655 693 686 788 897 889 Delaware 109 127 124 142 161 195 178 199 232 210 District of Columbia 192 188 309 293 311 336 360 292 416 411 Florida 2,166 2,300 2,644 2,841 3,161 3,505 3,546 3,806 4,127 4,535 Georgia 1,051 1,132 1,362 1,378 1,628 1,820 1,823 2,071 2,243 2,366 Hawaii 206 215 231 276 273 300 320 421 388 371 Idaho 86 102 125 141 132 125 137 181 184 192 Illinois 1,711 1,782 1,991 2,311 2,658 2,853 3,056 3,380 3,663 3,509 Indiana 703 805 863 925 987 1,145 1,216 1,145 1,508 1,488 Iowa 282 321 380 416 442 529 506 575 547 562 Kansas 277 292 368 398 400 426 423 495 498 554 Kentucky 444 476 541 589 695 759 798 732 948 900 Louisiana 755 868 995 1,027 1,179 1,309 1,320 1,466 1,625 1,557 Maine 110 111 109 146 135 160 154 198 230 204 Maryland 709 746 939 1,052 1,145 1,242 1,293 1,271 1,695 1,785 Massachusetts 654 765 868 908 1,020 1,164 1,191 1,319 1,419 1,435 Michigan 1,215 1,415 1,631 1,747 1,845 2,105 2,191 2,451 2,601 2,835 Minnesota 509 500 564 613 655 722 725 856 837 891 Mississippi 407 476 557 576 638 745 783 901 916 993 Missouri 736 775 887 979 1,065 1,137 1,219 1,323 1,462 1,470 Montana 76 71 110 112 139 127 136 146 168 140 Nebraska 171 188 221 221 244 290 271 319 341 344 Nevada 131 153 168 169 232 236 247 324 342 354 New Hampshire 96 105 125 137 145 151 138 169 183 158 New Jersey 1,305 1,383 1,567 1,754 1,916 2,092 2,158 2,437 2,668 2,631 New Mexico 184 250 242 258 333 311 321 362 434 467 New York 2,560 2,797 3,202 3,505 3,723 4,221 4,385 4,966 5,327 5,352 North Carolina 994 1,071 1,302 1,361 1,539 1,752 1,863 2,113 2,079 2,304 North Dakota 58 73 100 105 94 128 123 145 130 135 Ohio 1,451 1,648 1,837 1,938 2,006 2,344 2,415 2,576 3,148 3,263 Oklahoma 372 470 481 575 537 645 679 730 806 781 Oregon 303 343 397 410 482 471 539 573 566 571 Pennsylvania 1,802 1,952 2,262 2,608 2,650 2,906 2,820 3,440 3,775 3,689 Rhode Island 113 138 161 187 202 205 231 238 244 253 South Carolina 584 671 805 865 923 1,017 1,029 1,279 1,229 1,332 South Dakota 92 92 86 94 102 110 120 139 194 181 Tennessee 715 707 982 941 1,098 1,180 1,140 1,380 1,479 1,485 Texas 2,321 2,653 3,020 3,344 3,634 4,119 4,176 4,609 4,897 5,239 Utah 137 182 180 176 182 193 256 238 255 237 Vermont 50 52 65 65 92 61 74 80 111 92 Virginia 898 967 1,092 1,184 1,403 1,513 1,526 1,597 1,874 2,007 Washington 461 490 639 685 730 746 790 917 962 973 West Virginia 249 297 278 314 348 370 406 424 513 519 Wisconsin 564 669 747 759 840 947 926 1,037 1,079 1,119 Wyoming 37 50 44 36 49 39 52 46 69 66 -------- -------- -------- -------- -------- -------- -------- -------- -------- -------- 34,300 37,691 43,580 46,946 51,483 56,562 58,087 65,457 71,499 72,788 Includes all patients: residents of the 50 states, the District of Colulmbia, Puerto Rico and the Territories. * Values for cells with fewer than 10 patients are suppressed. Includes residents of 50 states and District of Columbia only. Table A.24 Incidence Rates Per Million Population Of Reported ESRD Therapy By State Adjusted By Age, Race and Sex Year 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 State Alabama 135.31 165.77 213.76 173.18 204.75 217.70 209.36 244.45 270.16 264.68 Alaska 145.57 106.47 178.75 123.09 144.92 177.74 192.21 736.18 1252.83 210.98 Arizona 170.17 192.70 217.58 206.71 237.99 286.99 253.01 290.03 287.46 306.33 Arkansas 135.43 157.58 154.94 161.58 202.64 203.99 212.59 251.76 276.47 256.16 California 164.54 177.09 200.11 214.91 228.64 226.24 227.94 273.86 281.13 269.55 Colorado 125.51 117.50 167.24 156.87 186.78 183.86 184.39 191.03 191.58 207.43 Connecticut 188.46 160.34 186.23 197.57 217.31 231.68 224.35 257.72 289.09 280.29 Delaware 174.96 183.87 197.65 216.46 233.11 280.48 244.61 254.71 308.32 261.21 District of Columbia 124.60 215.55 219.29 197.15 174.50 188.26 228.52 221.50 300.20 224.26 Florida 164.32 165.33 187.63 194.56 208.24 225.47 225.42 231.41 250.20 266.03 Georgia 157.49 157.87 192.30 180.73 212.46 231.30 230.49 256.13 326.28 341.66 Hawaii 117.71 103.10 222.57 143.89 126.37 155.73 165.81 192.17 159.07 133.48 Idaho 84.96 101.38 169.44 143.75 174.61 250.65 248.86 308.87 219.31 224.17 Illinois 155.19 157.93 176.40 202.33 228.77 246.78 258.28 282.87 306.02 289.72 Indiana 155.89 167.26 191.03 198.56 202.75 235.14 256.46 244.82 310.74 292.84 Iowa 189.64 159.00 197.32 222.25 208.76 264.66 230.81 295.51 278.75 315.29 Kansas 133.87 143.65 174.64 194.55 197.94 205.18 207.06 230.39 240.55 271.30 Kentucky 141.45 156.00 215.55 185.47 216.59 257.16 249.85 235.11 288.30 258.98 Louisiana 170.30 184.15 200.22 210.68 245.61 267.28 259.98 285.94 310.73 284.88 Maine 105.19 361.96 145.09 160.49 184.82 133.75 109.95 304.83 282.03 309.57 Maryland 136.73 138.56 171.46 192.62 204.54 219.45 222.31 213.64 276.16 283.12 Massachusetts 131.62 152.32 166.02 174.72 189.89 218.39 218.77 243.35 267.03 264.76 Michigan 142.26 159.17 184.34 194.75 203.44 227.24 233.08 264.32 275.64 291.02 Minnesota 164.24 179.25 180.61 205.32 203.67 217.01 219.54 262.27 275.58 265.64 Mississippi 133.65 156.42 193.69 172.28 205.23 224.28 224.66 295.00 300.86 278.66 Missouri 155.71 161.02 198.26 200.76 217.11 229.64 243.59 258.79 287.70 295.76 Montana 87.51 154.26 124.12 302.62 265.27 139.29 144.53 308.04 359.23 138.72 Nebraska 170.62 168.26 190.56 181.56 219.74 231.92 226.38 263.61 261.30 286.78 Nevada 157.71 169.17 199.37 170.15 211.68 196.50 203.54 248.25 245.05 231.70 New Hampshire 177.98 200.44 194.49 202.94 182.59 169.02 157.49 241.58 196.84 190.53 New Jersey 167.80 173.49 197.01 219.36 235.05 254.22 258.53 287.24 310.88 303.42 New Mexico 142.42 195.58 196.56 201.37 230.12 217.02 213.01 230.41 277.99 287.40 New York 137.53 148.06 167.98 181.66 192.99 216.19 222.05 248.60 262.47 262.64 North Carolina 133.52 141.51 170.62 173.69 195.32 215.17 226.26 250.91 268.15 291.01 North Dakota 88.53 110.18 817.76 193.94 136.26 204.49 784.04 401.31 1025.94 219.69 Ohio 147.95 164.88 195.40 191.90 192.18 223.47 227.07 242.26 295.00 298.05 Oklahoma 123.47 156.93 160.73 188.47 174.79 205.44 220.07 229.73 250.43 239.76 Oregon 161.58 156.97 195.21 168.62 222.30 184.08 218.94 243.50 233.06 229.72 Pennsylvania 159.23 165.69 215.59 227.85 223.66 239.76 232.40 287.72 317.06 294.43 Rhode Island 123.70 157.37 209.96 234.11 216.99 231.15 237.72 278.51 290.39 293.92 South Carolina 153.43 158.21 194.12 208.15 204.61 250.05 228.06 277.69 407.37 439.28 South Dakota 121.94 152.42 110.16 478.73 446.54 135.91 146.44 189.14 268.01 267.74 Tennessee 149.20 155.55 234.64 191.70 213.78 232.14 218.52 256.23 282.02 262.45 Texas 171.36 193.46 211.96 225.99 243.85 268.77 266.59 286.34 300.68 313.03 Utah 102.56 197.08 128.17 119.11 178.97 163.27 292.56 178.90 191.57 208.07 Vermont 191.44 268.34 608.48 103.99 271.40 164.58 198.17 477.46 338.37 238.73 Virginia 144.82 153.00 168.22 180.21 209.16 221.06 220.63 223.38 258.53 269.19 Washington 129.68 134.15 170.85 185.84 188.14 200.43 198.11 216.31 224.99 225.10 West Virginia 182.88 188.25 169.72 218.76 221.22 238.73 260.70 265.87 349.75 310.60 Wisconsin 161.67 181.93 195.79 203.10 216.05 249.71 239.54 256.33 278.17 277.85 Wyoming 133.76 176.28 167.21 124.65 297.29 131.29 248.04 129.18 152.53 247.59 Includes all patients: residents of the 50 states, the District of Colulmbia, Puerto Rico and the Territories. * Values for cells with fewer than 10 patients are suppressed. Includes residents of 50 states and District of Columbia only. Rates per million based on July 1, U.S. resident population by state or ESRD Network. The standard population is July 1, 1995, U.S. resident population by 5-year age groups, sex, and white/non-white race groups. Reference Tables: Incidence Of Reported ESRD Therapy USRDS 1998 Annual Data Report USRDS Patient Database Updated From HCFA REBUS September 1997. Quality Control Filters Applied. See section introduction and Chapter XIII discussion of the database and of the methodologies used.